Skip to main content

Market Overview

Solid Bio's DMD Gene Therapy Shows Promising Early Data, No New Safety Concerns, But Fails To Cheer Investors


Solid Biosciences Inc (NASDAQ: SLDBreported interim functional, biomarker data, and patient-reported outcome measures from its ongoing IGNITE Phase 1/2 trial of its lead gene therapy candidate, SGT-001 in Duchenne muscular dystrophy (DMD).

  • While IGNITE-DMD was designed to assess the microdystrophin protein expression and distribution, the company instead chose to highlight the functional and patient-reported outcomes at the 12-month mark.
  • Analysts and investors are less certain about the takeaway, driving the stock price lower. 
  • Data will be presented at the Muscular Dystrophy Association’s virtual clinical and scientific conference.
  • Sarepta Therapeutics Inc’s Duchenne gene therapy, which failed in a Phase 2 study readout, recently sported 1.7 point improvement in NSAA total score (all-important functional endpoint) compared to 0.9 on placebo. 
  • Solid Bio spurred even smaller improvement on the NSAA score at a mean of 1.0 point in the low dose group and 0.3 points in the high dose group.
  • The untreated control cohort exhibited a mean decline of 4.0 points.
  • On the 6-minute walk test, patients in the low-dose cohort walked 37 meters more on average, while the high-dose cohort had a mean improvement of 49.7 meters. Patients in the untreated control cohort exhibited a decline of 8.5 meters.
  • As for FVC, within a year untreated control cohort exhibited a mean decline of 10.7% on an absolute basis, while patients in the low dose and high dose cohorts exhibited a mean improvement of 3.9% and 16.7%, respectively, over the same period.
  • The biomarker data were more mixed. Though the high-dose group saw a sustained decline in creatine kinase (a marker of damage) of around 50%, the low dose cohort saw CK increase 166%, while the control group had an average CK increase of 17%.
  • Starting with the 7th patient in IGNITE-DMD, Solid is testing a second-generation construct that would cut the viral load by half and be administered within a modified regimen.
  • The Phase 1/2 DMD study was held down by clinical holds for almost three years. In March 2018, the FDA instituted a clinical hold after one patient was hospitalized due to a drop in platelet and red blood cell levels, followed by an immune reaction.
  • The agency cleared the study to resume in June 2018, only to halt it again in November 2019 after a patient developed complications similar to those that led to the first clinical hold.
  • Finally, in October last year, the FDA lifted the hold as the company agreed to lower the maximum weight of patients in the study, a change intended to boost safety.
  • Price Action: SLDB shares are trading 10.3% lower at $8.53 in premarket on the last check Tuesday.

Related Articles (SRPT + SLDB)

View Comments and Join the Discussion!

Posted-In: gene therapy Phase 2 TrialBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at